US Pharma MarketingFive burning questions for Isomorphic after its mammoth $2B+ raise
For privately held companies, Isomorphic’s raise is the second-largest in biotech history, surpassed only by Altos Labs’ $3 billion debut in 2022. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push…
Isomorphic Labs said Tuesday it had closed a $2.1 billion Series B round, cementing its bellwether role in using AI for drug discovery.
For privately held companies, Isomorphic’s raise is the second-largest in biotech history ...
Source: Endpoints News